Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 192

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 192
---
 also issued warrants to the lenders to purchase an aggregate 88,544shares of common stock, exercisable at $ 1.49per share, with such warrants expiring five yearsfrom issuance. Upon completing this issuance, the Company closed the senior secured convertible note offering after receiving a total of $ 790,000in proceeds.

Alliance Global Partners

On October 31, 2024, the Company consummated a public offering of an aggregate of (i) 395,574shares of common stock and 2,555,246pre-funded warrants to purchase up to 2,555,246shares of common stock, and (ii) 2,950,820common stock purchase warrants to purchase up to 2,950,820shares of common stock. Each share of common stock, or a pre-funded warrant in lieu thereof, was sold together with an accompanying warrant to purchase one share of common stock. AGP served as lead underwriter along with Boustead as co-underwriter.

The public offering price for each share of common stock and one accompanying warrant was $ 1.525. The public offering price of each pre-funded warrant and one accompanying common warrant was $ 1.524, which equals the price at which one share of common stock and accompanying warrant was sold to the public in this offering, minus $ 0.001. The exercise price of each pre-funded warrant is $ 0.001per share. Each warrant offered in the offering is exercisable for one share of common stock and has an initial exercise price equal to $ 1.40. The Company received aggregate gross proceeds from the offering of approximately $ 4.5million, before deducting placement agents’ fees and other offering expenses.

| F-19 |

<div align='center'>Index to Financial Statements</div>

| Report of Independent Registered Public Accounting Firm – Forvis Mazars, LLP (PCAOB ID 686)                          
 Consolidated Balance Sheets as of December 31, 2023 and 2022                                                         
 Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December 31, 2023 and 2022 | Page 
 F-21 
 F-22 
 F-23 |
|:---------------------------------------------------------------------------------------------------------------------|:-----|
| Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2023 and 2022            | F-24 |
| Consolidated Statements of Cash Flows for the years ended December 31,